Thymosin Alpha-1 & Hepatitis B: What Research Shows

Chronic hepatitis B remains one of the most significant infectious disease burdens worldwide, affecting hundreds of millions of people and increasing the risk of cirrhosis, liver failure, and hepatocellular carcinoma. As researchers continue to search for more effective treatment strategies, immunomodulatory peptides like thymosin-α1 have attracted growing scientific interest. A 2026 Cochrane systematic review published in The Cochrane Database of Systematic Reviews — one of the most rigorous forms of evidence synthesis in medicine — took a comprehensive look at what the available randomized controlled trial (RCT) data actually says about thymosin-α1 as a treatment option for people living with chronic hepatitis B (Naing et al., 2026).

What This Study Found

The Cochrane review by Naing and colleagues identified and analyzed 10 randomized controlled trials involving a total of 1,349 participants across six countries — Bangladesh, China, Italy, Korea, Singapore, and Taiwan. Participants ranged in age from 17 to 75 years, with the majority (77.5%) being male. The trials were published between 1991 and 2018, and follow-up periods ranged from six months to five years after the end of treatment.

The researchers evaluated thymosin-α1 both as a standalone therapy and in combination with other treatments, including interferon, pegylated interferon, lamivudine, entecavir, and tenofovir. The primary outcomes of interest were all-cause mortality, serious adverse events, and health-related quality of life.

The pooled analysis suggested several potentially favorable signals:

• All-cause mortality: Thymosin-α1 may reduce all-cause mortality compared to control interventions (RR 0.53, 95% CI 0.29 to 0.96; 3 studies, 907 participants), though this finding was rated as very low-certainty evidence.
• Serious adverse events: The study suggests a possible reduction in serious adverse events (RR 0.72, 95% CI 0.53 to 0.99; 5 studies, 1,056 participants), rated as low-certainty evidence — the highest certainty level observed across any outcome in this review.
• HBV-related mortality: Researchers found a similar risk ratio to all-cause mortality (RR 0.53, 95% CI 0.29 to 0.96; 3 studies, 907 participants; very low-certainty evidence).
• Non-serious adverse events: The data suggested a possible reduction in non-serious adverse events (RR 0.47, 95% CI 0.27 to 0.83; 5 studies, 300 participants; very low-certainty evidence).
• Health-related quality of life and histological improvement: The study suggests thymosin-α1 may have little to no meaningful effect on quality of life (based on a single trial of 161 participants) and that the effect on liver histology remains very uncertain due to substantial heterogeneity between studies (I² = 74%).
• HBV-related morbidity: The evidence is very uncertain about whether thymosin-α1 meaningfully impacts disease-related morbidity (RR 0.86, 95% CI 0.54 to 1.40).

Critically, the authors used the Cochrane Risk of Bias 2 (RoB 2) tool and rated the overall certainty of evidence as very low for all outcomes except serious adverse events, which was rated as low. The GRADE framework was applied throughout, and downgrading was primarily driven by study limitations, imprecision of pooled estimates, and in some cases, inconsistency across trials.

Clinical Significance

The significance of this Cochrane review lies both in what it finds and in what it cannot yet confirm. Thymosin-α1 is a naturally occurring thymic peptide known for its immunomodulatory and antiviral properties. It has been studied for decades across a range of viral infections, and is approved in some countries for use in hepatitis B and other conditions. The biological rationale for its use in chronic HBV is well-established: the peptide is understood to enhance T-cell function, promote cytokine activity, and support the immune system's ability to suppress viral replication.

However, as this Cochrane review makes clear, a plausible mechanism does not automatically translate into confirmed clinical benefit. The review found that while the direction of effect across several outcomes appears favorable for thymosin-α1, the certainty of the evidence is too low to draw firm conclusions. Wide confidence intervals, small participant numbers in several trials, and methodological concerns limit the strength of any recommendation.

Importantly, the review found no statistically significant differences in effect between subgroups receiving thymosin-α1 as monotherapy versus those receiving it alongside co-interventions such as nucleoside analogues or interferons. This consistency across administration strategies is worth noting, though it does not resolve the underlying uncertainty in the evidence base.

The absence of ongoing trials — the authors identified no active RCTs at the time of their search — is a notable gap. Sixteen studies were awaiting assessment due to incomplete reporting, which further underscores the need for well-conducted, adequately powered, and transparently reported research in this area.

Current Access and Compliance Context

Thymosin-α1 (trade name Zadaxin in some markets) is approved and commercially available in a number of countries, particularly across Asia and parts of Europe, where it has been used in clinical practice for chronic hepatitis B and other conditions for many years. In the United States, it is not currently approved by the FDA for any indication but may be accessible through research protocols or, in some contexts, via compounding pharmacies under physician supervision.

For patients and clinicians considering thymosin-α1, the regulatory and access landscape varies considerably by geography. Any use of thymosin-α1 — whether as part of a treatment protocol or in an investigational capacity — should occur under the direct guidance of a qualified, licensed healthcare provider who can assess individual risk, review current evidence, and ensure appropriate monitoring.

This Cochrane review, though constrained by the quality of available evidence, represents an important step in consolidating what the RCT literature shows. Its findings may inform clinical decision-making while also highlighting the urgent need for larger, better-designed trials with standardized outcome measures, longer follow-up periods, and transparent reporting practices.

What Patients Should Know

If you are living with chronic hepatitis B, the emergence of research on peptides like thymosin-α1 may be encouraging — but it is important to interpret this evidence carefully and in context.

Here are key takeaways from this Cochrane review for patients:

• The study suggests thymosin-α1 may offer some benefit in reducing mortality and adverse events, but the certainty of this evidence is rated as very low to low. This means that further well-designed research could substantially change these findings.
• No single trial in this review was large enough on its own to provide definitive conclusions, and the pooled analysis still leaves meaningful uncertainty.
• Thymosin-α1 was generally associated with a favorable safety signal across trials — with no increase in adverse events compared to controls — but this, too, should be interpreted cautiously given the evidence limitations.
• Established antiviral therapies for chronic hepatitis B (such as entecavir and tenofovir) remain the standard of care backed by robust evidence. Any interest in thymosin-α1 should be discussed with your treating physician in addition to, not instead of, your current treatment plan.
• Patients should not self-administer or source any peptide therapy without medical supervision.

Conclusion

The 2026 Cochrane systematic review by Naing and colleagues represents a rigorous and transparent assessment of the current evidence on thymosin-α1 for chronic hepatitis B. While the direction of findings is potentially encouraging — suggesting possible reductions in mortality and adverse events — the certainty of evidence remains low to very low, and firm clinical conclusions cannot yet be drawn. What is clear is that this field requires larger, better-designed, and more transparently reported randomized trials before definitive recommendations can be made.

If you are interested in learning more about peptide therapies and whether they may be appropriate for your individual health circumstances, we encourage you to consult with a qualified medical professional who is knowledgeable in this area. Visit peptideassociation.org/find-a-doctor to find a vetted healthcare provider near you.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice. The content presented here is based on published peer-reviewed research and is not intended to replace consultation with a qualified healthcare professional. Always speak with your physician or a licensed medical provider before making any decisions regarding your treatment or health management. The Peptide Association does not endorse any specific treatment, product, or therapy.

---

Citation (AMA Format):
Naing C, Ni H, Aung HH, et al. Thymosin-α1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9. doi:10.1002/14651858.CD014610.pub2. PMID: 42713852.